235 filings
Page 3 of 12
6-K
5ty8mzd85zgrw
16 Nov 22
Current report (foreign)
5:00pm
6-K
87zis jt7r
4 Aug 22
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
8:00am
6-K
pw2i7sir193nzkrmu513
7 Jul 22
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
8:47am
424B5
xtpxueoo9 q9d6ep8
1 Jul 22
Prospectus supplement for primary offering
4:30pm
6-K
rwzstj7rrm8ki4
29 Jun 22
Current report (foreign)
4:30pm
6-K
8vzgjjksp62aby
22 Jun 22
Current report (foreign)
5:00pm
6-K
q7szaso0kskg891ont
17 Jun 22
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
4:15pm
6-K
o0vm69h
17 May 22
Current report (foreign)
9:08am
6-K
7csqea4hlxj0
17 May 22
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
8:20am
6-K
x7mq2ujkc3
17 May 22
Galmed updates business and clinical development strategy to better leverage Aramchol’s anti-fibrotic effects
7:51am
6-K
xt7nd2
2 May 22
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial
7:07am
6-K
pi0loml
28 Apr 22
Current report (foreign)
8:04am
6-K
7odowwwzw5e0aik
3 Mar 22
Current report (foreign)
5:16pm
6-K
joksl
11 Jan 22
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
8:15am
6-K
pwunef7 31yq5
10 Jan 22
Galmed announces positive results of Phase 1 study of Amilo-5MER
8:11am
6-K
3o8539
8 Nov 21
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
8:25am
6-K
nnjbczm8k vq7m
1 Nov 21
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
10:23am
6-K
u9v90eff4bha
12 Oct 21
Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
7:00am
6-K
fpcdo buyxxgmw7a7
31 Aug 21
Current report (foreign)
4:30pm